Global Recombinant Plasma Proteins Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Recombinant Plasma Proteins Market Research Report 2024
For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins--such as coagulation factors, anticoagulants, immunoglobulins, and albumin--essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible--although with some limitations in productivity, costs, and immunogenic risks-
According to MRAResearch’s new survey, global Recombinant Plasma Proteins market is projected to reach US$ 106.4 million in 2033, increasing from US$ 92 million in 2022, with the CAGR of 2.1% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Plasma Proteins market research.
Key companies engaged in the Recombinant Plasma Proteins industry include CSL Limited, Shire (Takeda Pharmaceutical Company Limited), Octapharma, Novo Nordisk, Bayer, Bioverativ Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharming Group and Pfizer, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Recombinant Plasma Proteins were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Recombinant Plasma Proteins market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Recombinant Plasma Proteins market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
CSL Limited
Shire (Takeda Pharmaceutical Company Limited)
Octapharma
Novo Nordisk
Bayer
Bioverativ Therapeutics, Inc. (Sanofi)
Aptevo Therapeutics
Pharming Group
Pfizer
Segment by Type
Chinese Hamster Ovary (CHO) Cell Line
Baby Hamster Kidney (BHK) Cell Line
Human Embryonic Kidney (HEK) Cell Line
Others
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Recombinant Plasma Proteins report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Recombinant Plasma Proteins market is projected to reach US$ 106.4 million in 2033, increasing from US$ 92 million in 2022, with the CAGR of 2.1% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Plasma Proteins market research.
Key companies engaged in the Recombinant Plasma Proteins industry include CSL Limited, Shire (Takeda Pharmaceutical Company Limited), Octapharma, Novo Nordisk, Bayer, Bioverativ Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharming Group and Pfizer, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Recombinant Plasma Proteins were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Recombinant Plasma Proteins market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Recombinant Plasma Proteins market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
CSL Limited
Shire (Takeda Pharmaceutical Company Limited)
Octapharma
Novo Nordisk
Bayer
Bioverativ Therapeutics, Inc. (Sanofi)
Aptevo Therapeutics
Pharming Group
Pfizer
Segment by Type
Chinese Hamster Ovary (CHO) Cell Line
Baby Hamster Kidney (BHK) Cell Line
Human Embryonic Kidney (HEK) Cell Line
Others
Segment by Application
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Recombinant Plasma Proteins report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source